AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
May 28, 2021
31637_dirs_2021-05-28_be40eada-0fdf-4904-9323-a447e109d315.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-05-26
Reporting Person: SATO VICKI L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-26 | Common Stock | S | 894 | $64.902 | Disposed | 134861 | Direct |
| 2021-05-26 | Common Stock | S | 732 | $65.875 | Disposed | 134129 | Direct |
| 2021-05-26 | Common Stock | S | 40 | $66.715 | Disposed | 134089 | Direct |
Footnotes
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.58 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: Includes 3,253 restricted stock units.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.60 to $66.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $66.60 to 66.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.